Skip to main content
Deutsch

Detail

  1. Home
  2. Research
  3. Researcher Profiles
  4. Researcher Profiles
  5. Detail
Niema Kazem
Niema Kazem, MD

Department of Medicine II (Division of Cardiology)
Position: Doctor-in-training

ORCID: 0000-0002-6368-4580
T +43 1 40400 73516
niema.kazem@meduniwien.ac.at

Further Information

Keywords

Acute Coronary Syndrome; Atrial Fibrillation; Cardiopulmonary Resuscitation; Immunity, Cellular; T-Lymphocytes

Selected publications

  1. Kazem, N. et al., 2021. The Prognostic Potential of Growth Differentiation Factor-15 on Bleeding Events and Patient Outcome after Cardiac Surgery – A prospective cohort study. Thrombosis and Haemostasis. Available at: http://dx.doi.org/10.1055/a-1695-8327.
  2. Kazem, N., Sulzgruber, P. & Niessner, A., 2021. Dosage of direct oral anticoagulants during dual and triple antithrombotic therapy: a focus on the net clinical benefit. European Heart Journal - Cardiovascular Pharmacotherapy. Available at: http://dx.doi.org/10.1093/ehjcvp/pvab058.
  3. Kazem, N. et al., 2020. The Age-Specific Impact of Cellular Immunity on Long-Term Outcome after Acute Coronary Syndrome. Thrombosis and Haemostasis, 121(09), pp.1246–1254. Available at: http://dx.doi.org/10.1055/a-1340-2055.
  4. Kazem, N. et al., 2020. CD8+CD28null T Lymphocytes are Associated with the Development of Atrial Fibrillation after Elective Cardiac Surgery. Thrombosis and Haemostasis, 120(08), pp.1182–1187. Available at: http://dx.doi.org/10.1055/s-0040-1713096.
  5. Hofer, F., Kazem, N. et al., 2020. Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies. European Heart Journal - Cardiovascular Pharmacotherapy, 7(3), pp.189–195. Available at: http://dx.doi.org/10.1093/ehjcvp/pvaa027.